The evidence that fatty acid supplementation benefits children with attention-deficit hyperactivity disorder (ADHD) and should be considered as a fundamental part of any treatment protocol continues to grow.

In the latest randomised, double-blind trial 26 Canadian school children were divided into two groups (A and B). In the first phase, group A received an omega-3 supplement and group B received a placebo (sunflower oil). During the second phase, group B received the active n-3 PUFA supplement, which group A continued to take. The research was conducted over 16 weeks. A statistically significant improvement in symptoms was observed. 8 patients (four in each group) demonstrated marked clinical improvement.     

Click here to view the study abstract.

The role of essential fatty acid metabolism in the aetiology of ADHD is just beginning to be understood. Based on current research children with the condition may benefit from supplementing with around 3g daily of fish oil for approximately 3 months, continuing thereafter on a reduced dose of around 1g daily.